FDA Approves Vera's Trutakna for IgA Nephropathy — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA approved Trutakna, a medicine from biotech company Vera Therapeutics, on Tuesday for patients with IgA nephropathy (IgAN), a chronic autoimmune kidney disease.
- Trutakna treats IgAN, a condition in which immune antibodies accumulate in the kidneys and cause progressive loss of kidney function that can ultimately require dialysis.
- Vera Therapeutics CEO Marshall Fordyce told STAT the company is "extremely excited to bring Trutakna to patients" in an interview conducted ahead of the approval.
- IgA nephropathy has no cure and progresses silently, with the immune-driven kidney damage potentially ending in organ failure and the need for dialysis.
- The full clinical and competitive details of the Trutakna approval sit behind STAT+'s subscription paywall, limiting what broader coverage can show about efficacy or differentiation.
Why it matters: IgA nephropathy patients gain a newly FDA-approved treatment for a progressive autoimmune disease that can advance to organ failure and dialysis, while Vera Therapeutics clears a key regulatory milestone for its lead drug. The approval opens a commercial pathway for a condition with no cure and limited treatment options.
Ask SkimNews
